Entrada Therapeutics, Inc.
TRDA
$6.37
$0.111.76%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -95.74% | -96.53% | -91.75% | -97.94% | -65.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.74% | -96.53% | -91.75% | -97.94% | -65.23% |
| Cost of Revenue | 3.06% | -3.44% | 22.73% | 18.24% | 12.12% |
| Gross Profit | -179.43% | -875.50% | -214.43% | -157.34% | -137.74% |
| SG&A Expenses | -1.46% | -5.16% | 3.34% | 18.25% | 9.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.96% | -3.83% | 18.04% | 18.24% | 11.42% |
| Operating Income | -94.14% | -587.03% | -117.25% | -187.69% | -203.21% |
| Income Before Tax | -128.71% | -5,187.14% | -173.60% | -174.28% | -168.50% |
| Income Tax Expenses | -- | 104.92% | 135.16% | -93.55% | -- |
| Earnings from Continuing Operations | -128.93% | -3,562.78% | -214.52% | -178.32% | -173.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -128.93% | -3,562.78% | -214.52% | -178.32% | -173.84% |
| EBIT | -94.14% | -587.03% | -117.25% | -187.69% | -203.21% |
| EBITDA | -99.09% | -708.66% | -121.13% | -184.32% | -194.54% |
| EPS Basic | -124.74% | -3,498.56% | -208.16% | -164.76% | -160.22% |
| Normalized Basic EPS | -124.55% | -4,841.59% | -168.06% | -161.42% | -155.86% |
| EPS Diluted | -124.74% | -4,692.20% | -204.11% | -167.27% | -162.12% |
| Normalized Diluted EPS | -124.55% | -5,118.69% | -168.06% | -163.80% | -158.02% |
| Average Basic Shares Outstanding | 1.86% | 1.86% | 2.05% | 20.94% | 22.62% |
| Average Diluted Shares Outstanding | 1.86% | -3.36% | 2.05% | 16.42% | 18.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |